Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

Table 5 Results of the multivariate analyses of locoregional control, metastases-free survival and overall survival

	Hazard ratio	95 %-confidence interval	P
Locoregional control
Radiochemotherapy regimen
(Cisplatin 100 mg/m2 vs. Cisplatin weekly)	1.57	1.12–2.31	0.008
Gender
(female vs. male)	4.37	1.58–18.11	0.003
Primary tumor site
(oropharynx or larynx vs. others)	1.18	0.94–1.45	0.16
Metastases-free survival
ECOG performance score
(0–1 vs. 2)	5.63	2.19–14.11	<0.001
N-category
(N0-2a vs. N2b-3)	2.02	0.90–4.84	0.09
Histological grading
(G1–2 vs. G3)	1.81	1.26–2.66	0.002
Primary tumor site
(oropharynx or larynx vs. others)	1.15	0.88–1.50	0.30
Overall survival
Radiochemotherapy regimen
(Cisplatin 100 mg/m2 vs. Cisplatin weekly)	1.33	1.04–1.73	0.023
Gender
(female vs. male)	1.98	1.08–3.96	0.026
ECOG performance score
(0–1 vs. 2)	2.15	1.09–3.99	0.029
Primary tumor site
(oropharynx or larynx vs. others)	1.09	0.92–1.30	0.32

ISSN: 1471-2407